ScholarIQanswers from OpenAlex

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations

PaperCitations, authors & open-access status

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is a paper indexed in ScholarIQ from OpenAlex.

How many citations does First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations have?

ScholarIQcitation count

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations has 84 citations in the OpenAlex counts ScholarIQ stores.

When was First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations published?

ScholarIQyear

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations has 2023 year in the ScholarIQ index.

Open the OpenAlex record →

What is the open-access status of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

ScholarIQoa status

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations has green oa status in the ScholarIQ index.

Open the OpenAlex record →

What is the DOI of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

ScholarIQdoi

The DOI for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is on the source record.

Open the DOI →

What is the PMID of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

ScholarIQpmid

The PMID for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is on the source record.

Open the PMID →

What is the OpenAlex record for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations?

ScholarIQopenalex

The OpenAlex for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations is on the source record.

Open the OpenAlex →

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations

How many citations does First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations have?

When was First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations published?

What is the open-access status of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

What is the DOI of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

What is the PMID of First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

What is the OpenAlex record for First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations?

Related on ScholarIQ